Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8896 to 8910 of 9000 results

  1. First treatment to target heart condition set to benefit

    NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.

  2. NICE collaborates with international partner agencies to streamline the confidential marking process

    NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.

  3. New treatment option available for womb cancer

    A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.

  4. NICE publishes final draft guidance on Enhertu after commercial discussions conclude

    NICE does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.

  5. NICE recommends 'game changing' histology independent cancer drug

    Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).

  6. NICE recommends first treatment for rare blood disorder

    People with a rare blood disorder have access to a new treatment following draft guidance from NICE.

  7. NICE recommends innovative treatment for severe blood disorder for NHS use

    Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.

  8. NICE recommends new chemotherapy-free treatment option for people with untreated chronic lymphocytic leukaemia

    More than 1,000 people each year will benefit from NICE's recommendation.

  9. NICE recommends new drug for people living with obesity

    Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.

  10. People at risk of severe COVID-19 to have access to antiviral Paxlovid

    A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.

  11. Time to talk: about NICE's latest depression guidelines

    To mark Time to Talk Day (February 2) we spoke with Catherine Ruane, who acted as a carer for her father and sister, who both lived with depression.

  12. Non-invasive weight loss procedure can be an option to treat obesity

    A procedure which reduces the size of the stomach by two-thirds to help people living with obesity to lose weight has been deemed safe and effective to be used in the NHS, NICE has said.

  13. NICE's flexibility in evaluation of new health tech and fairer patient access

    Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.

  14. Celebrating the people who support NICE: International Volunteer Day

    Applauding the members of the public who donate their valuable experience and insight to NICE.

  15. NICE sets out further details on menopause guideline update

    NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.